Omeros announces closing of public offering to fund ongoing commercial and clinical activities
PDF: 2.4.15 WBB Securities Co-Manages $84 Million Public Offering for Omeros Corporation
For Immediate Release
February 4, 2015
SAN DIEGO, CA – WBB Securities acted as co-manager to a transaction for Omeros Corporation in an underwritten public offering that closed on February 3, 2015. The Company raised $84 million through the offering related to the sale of 3,444,831 shares of its common stock at a price of $20.03 per share and 749,250 pre-funded warrants to purchase up to an equal number of shares of its common stock at a price per warrant of $20.02, which was paid at closing. The pre-funded warrants have an exercise price of $0.01 per share and will expire on February 3, 2022. Gross proceeds from the offering were approximately $84.0 million, including approximately $15.0 million from the sale of the pre-funded warrants. The closing also included the sale of 449,325 shares of common stock sold pursuant to the option allowing the underwriters to purchase additional shares of common stock from Omeros, which the underwriters exercised in full. After deducting underwriting discounts and other estimated offering expenses, Omeros will receive net proceeds from the transaction of approximately $79.1 million.
Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the commercialization of its approved drug Omidria, research and development expenses, such as funding clinical trials, pre-clinical studies, manufacturing development and costs associated with otherwise advancing the company’s drug candidates toward New Drug Application submissions. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About WBB Securities
WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients.
The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. Our investment bank has participated in over 120 transactions leading to $2 billion placed. Whether raising capital or executing strategic transactions, our banking team is equipped to meet your financial needs and is comprised of some of the most knowledgeable people working in the life sciences domain. Our firm has been singled out for its equity research and analytics year after year from our peers for performance by the financial industry’s most highly regarded rankings organizations.
About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system.
